ALLO · Why this verdict
Why Allogene Therapeutics (ALLO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Value-trap signals include -47.4% operating margin compression and elevated leverage at a D/E of 1.9, risking further capital erosion. Bear case | Operating margin should move toward breakeven for the value-trap concern to ease. | →Stable |
| CounterDeep operating margin compression is expected pre-revenue for a clinical-stage biotech and doesn't necessarily indicate a structurally broken business model. | ||
Allogene has beaten estimates in all 3 of its last reported quarters, with an average surprise of +19.5%, a proof point on execution despite quality concerns elsewhere. Earnings | The earnings beat streak should continue at the next report in 39 days for the execution thesis to strengthen. | →Stable |
| CounterClinical-stage biotech earnings beats are often driven by expense timing rather than commercial progress, so the streak may not predict future results. | ||
Quality sits at 1.6, below the 4.0 floor, driven by negative free cash flow and no competitive moat, typical of a clinical-stage biotech burning cash. Quality breakdown | Quality score should improve if cash burn slows or a moat-building catalyst such as a partnership emerges. | →Stable |
| CounterPre-commercial cell-therapy biotechs are expected to burn cash while funding trials, so a low quality score may not reflect genuine business risk. | ||
The engine flags the stock's 15% short interest as justified given the underlying fundamentals, rather than a squeeze setup. Risk breakdown | Short interest should decline from 15% if the fundamental picture improves. | →Stable |
| CounterHigh short interest in a binary biotech name can still trigger a sharp squeeze on unexpected positive trial data regardless of whether it is fundamentally justified. | ||
The raw analyst price target was rejected as implausible at 4.1 times the current price, so the engine fell back to a technical take-profit, meaning the usual analyst-upside signal cannot be trusted here. Warnings | A revised, credible analyst target should emerge to restore confidence in the analyst-upside signal. | →Stable |
| CounterA stale or unadjusted analyst target following a major price decline is a data-lag issue, not necessarily evidence the original bullish view was wrong. | ||
Value-trap signals include -47.4% operating margin compression and elevated leverage at a D/E of 1.9, risking further capital erosion.
→StableBear case
- Expectation
- Operating margin should move toward breakeven for the value-trap concern to ease.
CounterDeep operating margin compression is expected pre-revenue for a clinical-stage biotech and doesn't necessarily indicate a structurally broken business model.
Allogene has beaten estimates in all 3 of its last reported quarters, with an average surprise of +19.5%, a proof point on execution despite quality concerns elsewhere.
→StableEarnings
- Expectation
- The earnings beat streak should continue at the next report in 39 days for the execution thesis to strengthen.
CounterClinical-stage biotech earnings beats are often driven by expense timing rather than commercial progress, so the streak may not predict future results.
Quality sits at 1.6, below the 4.0 floor, driven by negative free cash flow and no competitive moat, typical of a clinical-stage biotech burning cash.
→StableQuality breakdown
- Expectation
- Quality score should improve if cash burn slows or a moat-building catalyst such as a partnership emerges.
CounterPre-commercial cell-therapy biotechs are expected to burn cash while funding trials, so a low quality score may not reflect genuine business risk.
The engine flags the stock's 15% short interest as justified given the underlying fundamentals, rather than a squeeze setup.
→StableRisk breakdown
- Expectation
- Short interest should decline from 15% if the fundamental picture improves.
CounterHigh short interest in a binary biotech name can still trigger a sharp squeeze on unexpected positive trial data regardless of whether it is fundamentally justified.
The raw analyst price target was rejected as implausible at 4.1 times the current price, so the engine fell back to a technical take-profit, meaning the usual analyst-upside signal cannot be trusted here.
→StableWarnings
- Expectation
- A revised, credible analyst target should emerge to restore confidence in the analyst-upside signal.
CounterA stale or unadjusted analyst target following a major price decline is a data-lag issue, not necessarily evidence the original bullish view was wrong.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Allogene has beaten earnings in 3 straight quarters, but sub-floor quality driven by cash burn and no moat, value-trap margin and leverage signals, justified elevated short interest, and a rejected, implausible analyst price target all argue for treating the stock's headline upside with skepticism.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 6.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.2 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 4.6 |
- ▸Analyst upside: 300%
Insider
7.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
- ▸Negligible insider selling — $22,144 (0.003% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.6 |
| growth rank | 5.0 |
Technical
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.9 |
| support resistance | 2.6 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.0 |
| days to cover | 3.8 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 8.8 |
- ▸High short interest justified: 15%
- ▸High IV: 102%
- ▸Above max pain $0
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 65, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -52% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Insider at 7.5 could not lift the engine output above the verdict floor.
The strongest dimensions are Insider at 7.5, Catalyst at 7.5, and Momentum at 7.0; the weakest are Quality at 1.6, Technical at 2.9, and Peer rank at 3.9. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifAverage earnings surprise falls below 0% from the current +19.5%.
- P2Sub Floor Quality Cash Burn
Trip ifQuality score rises above 4.0 from the current 1.6.
- P3Value Trap Margin Leverage
Trip ifOperating margin rises above 0% from the current -47.4%.
- P4Justified Elevated Short Interest
Trip ifShort interest falls below 8% from the current 15%.
- P5Rejected Implausible Analyst Target
Trip ifA revised analyst target is published at less than 2x the current price, restoring analyst-target reliability.